NCT06649942View on ClinicalTrials.gov

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 24, 2025

Study Completion Date

March 24, 2025

Conditions

Healthy Volunteers - Male and Female

Interventions

DRUG

KP-001

KP-001 100 mg + placebo

DRUG

KP-001

KP-001 400 mg

DRUG

Moxifloxacin 400 mg

moxifloxacin 400 mg tablet

DRUG

Placebo

Placebo

Trial Locations (1)

91206

Parexel Early Phase Clinical Unit - Los Angeles, Glendale

Sponsors

Lead Sponsor

Kaken Pharmaceutical

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

Kaken Pharmaceutical

INDUSTRY